Alan B. Lancz & Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Alan B. Lancz & Associates’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,300	Closed	-$147K	–	175
2022 Q4	$147K	Sell	1,300 -500	-28%	-$46.9K	0.15%	168
2022 Q3	$153K	Hold	1,800	–	–	0.18%	136
2022 Q2	$155K	Buy	+1,800	New	+$143K	0.15%	155

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Alan B. Lancz & Associates's BMRN Position: Q1 2023 in Review

Alan B. Lancz & Associates sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 1,300 shares — an estimated $147K sold.

Alan B. Lancz & Associates first reported a position in BMRN in Q2 2022 and held it in 3 quarters. The position peaked at $155K in Q2 2022. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

Alan B. Lancz & Associates reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Alan B. Lancz & Associates sold 1,300 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $147K.
Alan B. Lancz & Associates first reported a position in BioMarin Pharmaceuticals in Q2 2022 and held it in 3 quarters.
Alan B. Lancz & Associates's BioMarin Pharmaceuticals position peaked at $155K in Q2 2022.
552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Alan B. Lancz & Associates's 13F filing for Q1 2023, filed 5 May 2023.